Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 281

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 281
---
 PARTY TRANSACTIONS |

The Company rents its office in Herzliya,
Israel from E.G Archimedes Ltd, which is under the Company’s executive chairman’s control, for a minimum monthly rental fee
of approximately $2.5. The rent agreement is in place until December 2025 (refer to Note 9(5)).

In 2024, the Company entered into short-term
loan agreements with certain directors and officers of the Company (see Note 5b and Note 5c).

| NOTE 15:- | SUBSEQUENT EVENTS |

| A. | In the first                                                                                   
 quarter of 2025, the Company received an additional loan in the amount of $100 under a bridge  
 loan agreement (see also Note 5). As of March 31, 2025, the Company received $350 under bridge 
 loan agreements.                                                                               |

<div align='center'>F-29</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 15:- | SUBSEQUENT EVENTS (Cons.) |

| 1. | A forward share                                                                                  
 split at a ratio of a two and a half-for-one (2.5-for-1) of the Ordinary Shares and preferred    
 shares. As a result of the Split, for every one (1) share of share either issued and outstanding 
 will be granted two and a half (2.5) new Ordinary Shares or preferred shares, as applicable.     |

| 2. | Contingent upon                                                                              
 the implementation of an initial public offering, the chairman of the Company’s board        
 of directors will be eligible to: (i) annual compensation of $250, to be paid on a quarterly 
 basis; (ii) a grant of 283,532 options with an exercise price of NIS 0.01; and (iii) at a    
 Qualified IPO (as defined below), a cash payment of $500. In addition, the holdings of the   
 chairman of the Company’s board of directors shall not be diluted any lower than 9.98%       
 as a result of any IPO with a total proceeds of no less than $6,000 (a “Qualified IPO”).     |

| 3. | Increase of authorized                             
 share capital from 3,000,000 to 22,500,000 shares. |

| 4. | Cancellation of                                                          
 the Company’s nominal